Timothy Pond

Timothy Pond

Auto-generated profile, based on publicly available information

Timothy Pond

Department of Psychiatry, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, 19104, United States; Mental Illness Research, Education and Clinical Center, Crescenz VAMC, United States

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 December 2014 in Addiction Biology
Verified
Journal Article
Open access
PDF file
HKHenry R. Kranzler
Henry R. Kranzler
SAStephen Armeli
Stephen Armeli
RWReagan Wetherill
Reagan Wetherill
RFRichard S. Feinn
Richard S. Feinn
HTHoward Tennen
Howard Tennen
TPTimothy Pond
Timothy Pond
Previous studies indicate that topiramate reduces alcohol use among problem drinkers, with one study showing that the effect was moderated by a polymorphism (rs2832407) in GRIK1, the gene encoding the GluK1 kainate subunit. We examined whether the interactive effect of medication and genotype (1) altered the association between daily self‐efficacy and later‐day drinking; and (2) had an indirect effect on drinking via self‐efficacy. In a 12‐week, placebo‐controlled trial of topiramate, we used daily interactive voice response technology to measure self‐efficacy (i.e. confidence in avoiding heavy drinking later in the day) and drinking behavior in 122 European‐American heavy drinkers. Topiramate's effects on both self‐efficacy and drinking level were moderated by rs2832407. C‐allele homozygotes treated with topiramate showed higher levels of self‐efficacy and lower levels of nighttime drinking across the 12‐week trial. Further, the interactive effect of topiramate and genotype on mean nighttime drinking levels was mediated by mean levels of self‐efficacy. By modeling topiramate's effects on nighttime drinking across multiple levels of analysis, we found that self‐efficacy, a key psychologic construct, mediated the effect of topiramate, which was moderated by rs2832407 genotype. Thus, it may be possible to use an individualized assessment (i.e. genotype) to select treatment to optimize the reduction in heavy drinking and thereby provide a personalized treatment approach.

1 December 2014 in Alcohol, Clinical and Experimental Research
Verified
Journal Article
Open access
PDF file
HKHenry R. Kranzler
Henry R. Kranzler
RWReagan Wetherill
Reagan Wetherill
RFRichard S. Feinn
Richard S. Feinn
TPTimothy Pond
Timothy Pond
JGJoel Gelernter
Joel Gelernter
JCJonathan Covault
Jonathan Covault
Background: We examined whether the effects of topiramate and a single nucleotide polymorphism (rs2832407) in GRIK1, which encodes a kainate receptor subunit, persisted following a 12‐week, placebo‐controlled trial in 138 heavy drinkers with a treatment goal of reduced drinking. During treatment, topiramate 200 mg/d significantly reduced heavy drinking days and increased the frequency of abstinent days (Am J Psychiatry, 2014, 171:445). In the European‐American (EA) subsample (n = 122), rs2832407 moderated the treatment effect on heavy drinking.Methods: Patients were re‐interviewed 3 and 6 months after the end of treatment. During treatment, we obtained 92.4% of drinking data, with 89.1 and 85.5% complete data at the 3‐ and 6‐month follow‐up visits, respectively. We examined 4 outcomes over time in the overall sample and the EA subsample: percent heavy drinking days (PHDD), percent days abstinent (PDA), serum γ‐glutamyl transpeptidase (GGTP) concentration, and a measure of alcohol‐related problems.Results: In the full sample, the lower PHDD and higher PDA seen with topiramate treatment were no longer significant during follow‐up. Nonetheless, the topiramate‐treated patients had lower alcohol‐related problem scores during treatment and both follow‐up periods. Further, in the EA subsample, the greater reduction in PHDD seen with topiramate treatment in rs2832407*C‐allele homozygotes persisted throughout follow‐up, with no significant effects in A‐allele carriers. A reduction in GGTP concentration was consistent with the reduction in heavy drinking, but did not reach statistical significance.Conclusions: There are persistent therapeutic effects of topiramate in heavy drinkers, principally in rs2832407*C‐allele homozygotes.

1 August 2021 in Drug and Alcohol Dependence
Verified
Journal Article
Closed access
HKHenry R. Kranzler
Henry R. Kranzler
EHEmily E. Hartwell
Emily E. Hartwell
RFRichard Feinn
Richard Feinn
TPTimothy Pond
Timothy Pond
KWKatie Witkiewitz
Katie Witkiewitz
RCRichard C. Crist
Richard C. Crist